Aleman-Mateo H, Carreon VR, Macias L, Astiazaran-Garcia H, Gallegos-Aguilar AC, Enriquez JR
Early to moderate type 2 diabetes For patients with type 2 diabetes who have not achieved adequate control with metformin alone, GLP-1 receptor agonists are increasingly the second-line choice
SABOURET, is now available as a preprint in Archives of Medical Science (AMS) The problem GLP-1 receptor agonists and SGLT2 inhibitors have become central components of cardiovascular, renal, and metabolic care
Pharmacological activation or genetic restoration of this axis, using agents such as DCA to inhibit pyruvate dehydrogenase kinase, reactivated mitochondrial oxidative phosphorylation, increased reactive oxygen species production, and triggered apoptosis in cancer cells